The objective of this study was to correlate the expression of topoisomerase (topo) IIα to in vitro drug sensitivity and to the clinical outcome in patients with acute leukaemia. Leukaemic cells were isolated from bone marrow or blood from 94 patients. Topo IIα mRNA (n=58) and protein (n=60) expression was determined by real-time RT-PCR and flow cytometry, respectively. In both groups, chemosensitivity testing by a bioluminescence ATP assay was performed to a variable extent for both topo IIα poisons and non-topo IIα targeting drugs. Topo IIα mRNA expression varied with relative values ranging from 0.03 to 14.20 (median 1.10). The median value for topo IIα protein-positive cells was 23% (range 0-99%). Cell samples from patients with a high (>median value) percentage of topo IIα-positive cells were significantly more sensitive to the topo IIα active drugs etoposide and daunorubicin, and showed a borderline value for idarubicin (p=0.08), while there was no difference for non-topo IIα targeting drugs. However, we did not find any significant differences in mRNA expression or the percentage of topo IIα-positive cells in patients who achieved complete remission after at most two induction courses compared with those who did not, nor did we find any difference in survival when patients with high mRNA expression/percentage of topo IIαpositive cells were compared with patients with low values. We conclude that expression of topo IIα, determined as percentage of topo IIα-positive cells, in leukaemic cells correlates to chemosensitivity in vitro against topoisomerase poisons but that it does not predict clinical outcome in acute leukaemia.
Introduction
A major problem in the treatment of acute leukaemia is intrinsic or acquired resistance to cytostatic drugs. Several mechanisms of such drug resistance have been identified in experimental tumour systems (1) . The one most extensively studied is drug transport involving efflux pumps, among which p-glycoprotein has been shown to be of prognostic value (2) . Another level of resistance, drug targets, may involve topoisomerases.
Topoisomerase IIα (topo IIα) is a nuclear enzyme, which is important for transcription, replication and mitosis. The enzyme introduces transient double-strand breaks, thereby catalyzing changes in DNA topology by passing a doublestranded DNA helix through this transient break site which is then religated (3) . In normal cells, topo IIα is expressed in a cell cycle-dependent pattern with low levels in the G0/G1 phase and high levels in S/G2/M (4) . There are data indicating that topo IIα expression in malignant cells is less cell cycle dependent, and that topo IIα could be significantly expressed in G0/G1 as well (5) (6) (7) (8) .
Topo IIα is the primary target for cytostatic drugs, such as anthracyclines, epipodophyllotoxins and amsacrine (9) . These drugs convert the reversible double-strand break into an irreversible one, a 'cleavable complex' (10) ; and this DNA cleavage is considered the main mechanism to induce apoptosis, although other mechanisms could also be of importance (11) . In different tumour cell lines, including leukaemic cells, low topo IIα content and/or activity has been correlated to drug resistance (12) (13) (14) (15) (16) , although there have been contradictory results (17) . Previous reports on topo IIα expression and clinical outcome have been negative regarding both mRNA (18, 19) and protein (20) level, with one exception (21) . In a previous study on acute leukaemia, we demonstrated that topo IIα protein is also expressed in the G0/G1 cell cycle phase, and suggested a correlation to clinical outcome (7) .
The aim of the present study was to correlate topo IIα mRNA and protein expression to chemosensitivity in vitro and to further investigate the impact of topo IIα expression on response to induction therapy and prognosis in acute leukaemia. Table I . Patient characteristics and topo IIα expression. Leukocyte  Karyotype  Cytogenetic Response a BM/PB b  Topo II protein c  Topo II  secondary  subtype  count x10 9  risk group  - Table I -
Materials and methods
Patients. Bone marrow (BM, n=70) or peripheral blood (PB, n=24) samples, collected from 94 patients with newly diagnosed acute leukaemia, were investigated after ethics committee approval and informed consent. The patients had a mean age of 58 (range 18-84); 61 were women and 33 were men. Seventy-six patients had de novo AML and 12 had AML secondary to myelodysplastic syndrome (n=4), CML (n=3), Hodgkin's lymphoma (n=1), essential thrombocythemia (n=1), or cytostatic treatment for other reasons (n=3). Three patients had pre-B-ALL and 3 patients had T-ALL, all de novo. Cytogenetic analysis was routinely performed for 85 patients. Based on criteria derived from the MRC AML 10 trial (22), 7 patients with AML were defined as having favourable karyotype whereas 61 and 11 patients had intermediate or adverse karyotype, respectively. For patient data in detail, see Table I .
Samples from 58 patients were vitally frozen and used for real-time RT-PCR. Forty-nine of these patients were evaluable for clinical response to induction treatment. Fresh samples from 60 patients (including 24 of the patients who provided samples for RT-PCR) were used for flow cytometry. In this group, 40 patients were evaluable for clinical response. In both groups, patients who were not evaluable for clinical response received only palliative treatment due to poor performance status; or, in a few cases, died early during induction treatment.
Patients with AML who were evaluable for clinical response to induction treatment received at least one course of induction therapy containing an anthracycline or mitoxantrone (1 patient received amsacrine) in combination with cytarabine. Thirty patients received an additional drug which in 14 cases was etoposide. When a second induction course was given, it contained amecrine instead of anthracycline or mitoxantrone in 17 cases, and etoposide was added in 23 cases. Patients with ALL received treatment according to the Swedish Adult ALL Group protocol, which includes daunorubicin in the first induction course and amsacrine in the second induction course.
Complete remission (CR) was defined as ≤5% bone marrow blasts after recovery from induction therapy. In three cases, response was defined as CR despite the presence of 5.5-6% blasts. Clinicians had considered these patients to be in CR and the patients remained in CR during follow-up. A patient was defined as a responder if CR was achieved with at most two induction courses and as a non-responder otherwise.
Laboratory methods. For real-time RT-PCR, vitally frozen mononuclear cells, continually collected at the participating hospitals, were used. The leukemic cell line CEM, cultured with 89% RPMI, 10% fetal bovine serum and 1% L-glutamine, was used to construct standard curves. Thawed patient sample cells and fresh CEM cells were washed in Dulbecco's PBS (Gibco, Invitrogen, Paisley, UK) before RNA isolation. RNA was isolated using QIAamp RNA Blood Mini kit (Qiagen, Hilden, Germany) following the manufacturer's instructions, and was stored at -80˚C. The quality and quantity of RNA was determined using RNA chips with RNA 6000 Nano Reagents & Supplies (Agilent Technologies, Waldbronn, Germany) with a Bioanalyzer (Agilent Technologies).
cDNA was synthesized from 400 ng RNA from each patient sample or cell line to a volume of 40 μl, which was stored at -20˚C. For cDNA synthesis, Omniscript RT kit (Qiagen) or first-strand synthesis kit for RT-PCR (Roche, Mannheim, Germany) with OligodT primer, was used. To perform a realtime PCR, a mix containing Taqman Universal PCR Master mix (Applied Biosystems), primer (1 μM), probe (0.25 μM), 2 μl cDNA, and water to a total volume of 25 μl was prepared and the samples were amplified in duplicates using ABI PRISM 7700 (Applied Biosystems, Weiterstadt, Germany). Primers and probes for the house-keeping gene ß-actin and topo IIα are shown in Table II .
Standard curves were constructed for ß-actin and topo IIα by serial dilutions of the purified (QIAquick Gel Extraction kit, Qiagen) amplification products using cDNA from the leukemic cell line CEM. Patient samples were related to the standard curves, giving a relative quantification of the gene product. Topo IIα expression (mean value of the duplicates) was normalized by division with the ß-actin expression. This quotient was used for statistics. Flow cytometry was performed as previously described (7) .
Chemosensitivity in vitro was tested by a bioluminescence ATP assay as previously described (23) . Briefly, ATP levels in a specific cell type are relatively constant in living cells but degrade rapidly if the respiratory cycle is disturbed. The level of ATP is therefore proportional to the number of viable cells in a sample. ATP levels are determined in cell samples cultured with cytostatic drugs, and expressed as a percentage of living cells in comparison to samples cultured without cytostatic drugs, that is, a resistant cell sample will achieve a high percentage value in this test. Every group tested for a certain drug was divided into two groups, using as cut-off the median value for topo IIα mRNA expression or percentage of topo IIα-positive cells, respectively. Thus, for every tested drug, one group with 'low' topo IIα mRNA/percentage of topo IIα protein-positive cells and one group with 'high' topo IIα mRNA /percentage of topo IIα protein-positive cells were compared according to chemosensitivity in vitro.
Statistics. The Mann-Whitney test was used for comparison of mRNA and protein expression in the groups defined by clinical response, cytogenetic risk and de novo/secondary AML. Survival curves were calculated according to Kaplan-Meier, and the log-rank test was used for comparison of survival. Student's t-test for independent groups was used for comparison of chemosensitivity in vitro in different groups of patient samples. Statistics were calculated using SPSS 11.5 for Windows (SPSS Inc., Chicago, IL).
Results
Topo IIα mRNA. Topo IIα mRNA expression varied widely, with relative values ranging from 0.04 to 15.32 arbitrary units (median 1.10) and a skewed distribution (Fig. 1) . No statistically significant differences were found between topo II mRNA expression in samples from patients in different cytogenetic risk groups or from patients with de novo and secondary AML.
Topo IIα protein. The overall expression of topo IIα varied, with median 23% positive cells (range 0-99%) and a bimodal distribution (Fig. 2) . Cells in the S/G2/M cell cycle phase expressed topo IIα to a higher extent than cells in the G0/G1 cell cycle phase; median 70.5% (range 0-98%) positive cells vs. 20.5% (0-99%).
In samples from patients with favourable karyotype (n=5), the proportion of topo IIα-positive cells had a median of 71% (range 1-88%) overall, 69% (1-88%) for cells in the G0/G1 phase, and 75% (1-92%) for cells in S/G2/M, while samples from patients with intermediate karyotype (n=35) showed positivity with a median of 21% (0-95%) overall, 18% (0-96%) in G0/G1, and 71% (0-98%) in S/G2/M. Samples from patients with adverse karyotype (n=9) showed positivity with a median of 13% (0-99%) overall, 6% (0-99%) in G0/G1 and 55% (12-98%) in S/G2/M. These differences were not statistically significant.
Overall, samples from patients with secondary AML (n=9) showed topo IIα positivity with a median of 6% (0-95%), and samples from patients with de novo AML (n=45) with a median of 24% (0-99%), p=0.04. For cells in G0/G1, the median was 6% (0-96%) for secondary AML and 32% (0-99%) for de novo AML, p=0.04, while for cells in S/G2/M, the median was 55% (0-91%) for secondary AML and 74% (0-98%) for de novo AML, not significant (n.s).
Topo IIα mRNA and protein. Topo IIα mRNA expression and percentage of topo IIα-positive cells were determined in 24
patients. There was no correlation between mRNA expression and percentage of topo IIα-positive cells.
Chemosensitivity in vitro. Patient samples with low topo
IIα mRNA tended to be less sensitive to topoisomerase poisons, but not to other drugs (Fig. 3 ). This tendency was stronger for samples with a low percentage of topo IIα protein-positive cells, and reached statistical significance for daunorubicin and etoposide (Fig. 4) . Since RT-PCR and flow cytometry were performed in different patient groups, it was not possible to make a direct comparison between the groups tested for topo IIα mRNA and percentage of topo IIα protein-positive cells, respectively. Clinical outcome. Of the 49 clinically evaluable patients tested for topo IIα mRNA, 37 were defined as responders and 12 as non-responders. Median topo IIα mRNA expression was almost the same in the responder group (1.26; range 0.04-15.32) and in the non-responder group (1.08; 0.24-6.13) ( Fig. 5 ). Survival was investigated by dividing the patients into 2 groups with the median topo IIα mRNA expression as cutoff. Median survival was 21 months (95% CI: 3-39) in the group with low topo IIα mRNA expression and 15 months (95% CI: 6-25) in the group with high topo IIα mRNA expression (n.s.). Similar results were obtained when patients who were not evaluable for response to induction therapy were excluded (data not shown).
Of the 40 clinically evaluable patients tested for topo IIα protein expression, 30 were defined as responders and 10 as non-responders. There was no significant overall difference in percentage of topo IIα-positive cells between samples from responders and non-responders (median 35% and 25% positive cells respectively; Fig. 6 ), and the same was true for cells in G0/G1 (29% and 18.5%) and S/G2/M (67.5% and 71.5%). Survival was compared between patients with low and high topo IIα expression, using the median (23% positive cells) as cut-off. Median survival was 7 months (95% CI: 0-16) in the group with <23% positive cells and 10 months (95% CI: [6] [7] [8] [9] [10] [11] [12] [13] [14] in the group with >23% positive cells (n.s.). Results regarding survival were similar when patients who were not evaluable for response to induction treatment were excluded (data not shown).
Discussion
This study included bone marrow and blood samples from 88 patients with AML and six patients with ALL. The presented results on clinical outcome did not change when patients with ALL were excluded from the statistical calculations (data not shown). PB and BM samples were both used in this study. There are data indicating that normal PB mononuclear cells express very low amounts of topo IIα mRNA (24) . In this study, there was no statistically significant difference between topo IIα mRNA expression in PB and BM samples (data not shown), indeed some of the highest relative values were found in PB samples (Table I ).
The reported difference in topo IIα protein positivity in de novo and secondary AML does not allow any firm conclusion since the number of patients with secondary AML was small. Still, one could speculate about down-regulation of topo IIα in secondary AML as a contribution to poor prognosis. Chemosensitivity testing in vitro showed, as could be theoretically expected, that samples with a lower percentage of topo IIα-positive cells were more resistant against topo IIα poisons, particularly daunorubicin and etoposide, but not against non-topo IIα targeting drugs. The same pattern, although less evident, was seen for topo IIα mRNA expression. This supports the hypothesis that downregulation of topo IIα can be a resistance mechanism against these drugs, also in the clinic.
However, samples from responders did not express significantly more topo IIα mRNA or protein than samples from non-responders. This is in accordance with the results of Kaufmann et al (20) , who investigated topo IIα at the protein level using Western blotting in 41 newly diagnosed AML patients, Galmarini et al (19) who determined topo IIα mRNA by RT-PCR in 77 AML patients, and by McKenna et al (18) in a study of mRNA expression in 16 AML patients.
In this study, there was no difference in survival for patients with 'high' or 'low' expression of topo IIα mRNA or protein.
Again, this is in agreement with Galmarini et al (19) . In contrast, however, Lohri et al (21) , who also investigated topo IIα mRNA expression, using quantitative RT-PCR in samples from 57 patients with AML, found that the group with high topo IIα mRNA expression had a significantly better prognosis, defined both as progression-free survival and as overall survival.
The failure to demonstrate a correlation between topo IIα expression and clinical outcome could have several explanations. As AML patients are generally treated with both anthracyclines and cytarabine, the anthracycline's, and thereby topo IIα's, effect on clinical outcome could be obscured.
Another explanation could be heterogeneously distributed topo IIα (20) . The mRNA expression is determined on average and there could be subpopulations of cells, with very low expression of topo IIα, which are responsible for poor response to induction treatment or relapse. Our flow cytometry method determines the percentage of topo IIα-positive cells but not the average or individual cell content of topo IIα protein, and this could possibly explain the lack of concordance between topo IIα mRNA expression and percentage of topo IIα-positive cells. The in vitro data on chemosensitivity support the theory that subpopulations with low topo IIα protein content could be of importance for resistance to topoisomerase poisons, and that the percentage of topo IIα-positive cells determined by flow cytometry reflects this resistance better than the average mRNA expression determined by RT-PCR.
Another factor of importance could be post-translational modification of topo IIα activity. It has been demonstrated that cell-cycle specific phosphorylation is important in regulation of human topo IIα enzymatic activity (25, 26) , and that formation of 'cleavable complexes' is reduced in a mutated HL-60 leukaemic cell line with impaired phosphorylation of topo IIα in the presence of topoisomerase-targeting drugs (VP-16 and amsacrine) (27) compared to unmutated HL-60. Another mechanism that could enhance enzymatic activity is the formation, together with other proteins, of a 'toposome' during mitosis (28) . Obviously, neither of these possible activity regulators are taken into account in the present study.
In conclusion, despite a correlation to chemosensitivity in vitro, this study could not verify any predictive value of topo IIα mRNA or protein expression on clinical outcome in acute leukaemia. Since topo IIα is the main target for important cytostatic drugs in treatment of acute leukaemia, further attempts to link topo IIα to clinical response are reasonable, preferably with methods taking heterogeneous distribution and enzyme activity into account.
